WO2006076121A3 - Tissue regeneration - Google Patents

Tissue regeneration Download PDF

Info

Publication number
WO2006076121A3
WO2006076121A3 PCT/US2005/045627 US2005045627W WO2006076121A3 WO 2006076121 A3 WO2006076121 A3 WO 2006076121A3 US 2005045627 W US2005045627 W US 2005045627W WO 2006076121 A3 WO2006076121 A3 WO 2006076121A3
Authority
WO
WIPO (PCT)
Prior art keywords
introducing
treatment agent
cellular component
delivery device
region
Prior art date
Application number
PCT/US2005/045627
Other languages
French (fr)
Other versions
WO2006076121A2 (en
Inventor
Evgenia Mandrusov
Charles Claude
Eugene T Michal
Original Assignee
Advanced Cardiovascular System
Evgenia Mandrusov
Charles Claude
Eugene T Michal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cardiovascular System, Evgenia Mandrusov, Charles Claude, Eugene T Michal filed Critical Advanced Cardiovascular System
Publication of WO2006076121A2 publication Critical patent/WO2006076121A2/en
Publication of WO2006076121A3 publication Critical patent/WO2006076121A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3873—Muscle tissue, e.g. sphincter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules

Abstract

A method including positioning a delivery device at a location in a vessel within a mammalian body, introducing a first treatment agent including a cellular component through the delivery device, and introducing a different second treatment agent disposed in a carrier through the delivery device. A method including identifying an infarct region within myocardial tissue and a border region of perfused tissue adjacent the infarct region, introducing a treatment agent including a cellular component to the border region, and introducing a plurality of microparticles to the infarct region. A kit including a treatment agent including a cellular component in a form suitable for percutaneous delivery, and a separate amount of a plurality of microparticles in a form suitable for percutaneous delivery.
PCT/US2005/045627 2004-12-17 2005-12-16 Tissue regeneration WO2006076121A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/016,017 US7854944B2 (en) 2004-12-17 2004-12-17 Tissue regeneration
US11/016,017 2004-12-17

Publications (2)

Publication Number Publication Date
WO2006076121A2 WO2006076121A2 (en) 2006-07-20
WO2006076121A3 true WO2006076121A3 (en) 2007-01-11

Family

ID=36596042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045627 WO2006076121A2 (en) 2004-12-17 2005-12-16 Tissue regeneration

Country Status (2)

Country Link
US (2) US7854944B2 (en)
WO (1) WO2006076121A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121719A1 (en) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8568761B2 (en) * 2005-07-15 2013-10-29 Cormatrix Cardiovascular, Inc. Compositions for regenerating defective or absent myocardium
US20070014869A1 (en) * 2005-07-15 2007-01-18 Cormatrix Cardiovascular, Inc. Compositions for reconstruction, replacement or repair of intracardiac tissue
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US20100272679A1 (en) * 2007-12-14 2010-10-28 Penn Marc S Compositions and methods of promoting wound healing
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
WO2012094512A2 (en) * 2011-01-05 2012-07-12 The Cleveland Clinic Foundation Myocardial tissue targeting peptides
PL401689A1 (en) * 2012-11-20 2014-05-26 Zachodniopomorski Uniwersytet Technologiczny W Szczecinie Agent for purifying water from dissolved phosphorus compounds
JP6681872B2 (en) 2014-03-21 2020-04-15 ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Method for preparing final sterile hydrogel derived from extracellular matrix
EP3402876B1 (en) 2016-01-13 2021-10-13 University of Pittsburgh- Of the Commonwealth System of Higher Education Vascular extracellular matrix hydrogel

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040070A2 (en) * 2000-11-15 2002-05-23 Bio Syntech Canada Inc. Method for restoring a damaged or degenerated intervertebral disc
WO2002087623A1 (en) * 2001-04-27 2002-11-07 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
WO2003064637A1 (en) * 2001-11-06 2003-08-07 Medtronic, Inc. Method and system for myocardial infarction repair
WO2004050013A2 (en) * 2002-11-29 2004-06-17 The Regents Of The University Of California Material compositions and related systems and methods for treating cardiac conditions
WO2004091592A2 (en) * 2003-04-15 2004-10-28 Guidant Corporation, V.I. Methods and compositions to treat myocardial conditions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2194144B (en) 1986-08-22 1990-04-25 American Cyanamid Co Stable pharmaceutical gel preparation
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US4794931A (en) 1986-02-28 1989-01-03 Cardiovascular Imaging Systems, Inc. Catheter apparatus, system and method for intravascular two-dimensional ultrasonography
US5588432A (en) 1988-03-21 1996-12-31 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials, and ablating tissue
US5372138A (en) 1988-03-21 1994-12-13 Boston Scientific Corporation Acousting imaging catheters and the like
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5049130A (en) 1988-12-23 1991-09-17 Cardiovascular Imaging Systems, Inc. System and method for pressure filling of catheters
DE3908183C5 (en) 1989-03-14 2005-01-05 Kiekert Ag Motor vehicle door lock
US5024234A (en) 1989-10-17 1991-06-18 Cardiovascular Imaging Systems, Inc. Ultrasonic imaging catheter with guidewire channel
US5485486A (en) 1989-11-07 1996-01-16 Qualcomm Incorporated Method and apparatus for controlling transmission power in a CDMA cellular mobile telephone system
US5202745A (en) 1990-11-07 1993-04-13 Hewlett-Packard Company Polarization independent optical coherence-domain reflectometry
JP3367666B2 (en) 1990-12-17 2003-01-14 カーディオヴァスキュラー イメイジング システムズ インコーポレイテッド Vascular catheter with low profile distal end
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5465147A (en) 1991-04-29 1995-11-07 Massachusetts Institute Of Technology Method and apparatus for acquiring images using a ccd detector array and no transverse scanner
JP3479069B2 (en) 1991-04-29 2003-12-15 マサチューセッツ・インステチュート・オブ・テクノロジー Method and apparatus for optical imaging and measurement
US6134003A (en) 1991-04-29 2000-10-17 Massachusetts Institute Of Technology Method and apparatus for performing optical measurements using a fiber optic imaging guidewire, catheter or endoscope
US5291267A (en) 1992-01-22 1994-03-01 Hewlett-Packard Company Optical low-coherence reflectometry using optical amplification
EP0626823B1 (en) 1992-02-21 2000-04-19 Boston Scientific Limited Ultrasound imaging guidewire
US5365325A (en) 1992-08-10 1994-11-15 Hitachi, Ltd. Method of multi-color recording using electro-photography process and apparatus therefor wherein mixed colors generation is prevented
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) * 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JP2833456B2 (en) 1993-11-22 1998-12-09 株式会社東芝 Insertable ultrasound system
US5464395A (en) 1994-04-05 1995-11-07 Faxon; David P. Catheter for delivering therapeutic and/or diagnostic agents to the tissue surrounding a bodily passageway
US6056744A (en) 1994-06-24 2000-05-02 Conway Stuart Medical, Inc. Sphincter treatment apparatus
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5740808A (en) 1996-10-28 1998-04-21 Ep Technologies, Inc Systems and methods for guilding diagnostic or therapeutic devices in interior tissue regions
WO1996011671A1 (en) 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
US6099864A (en) 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules
US5900433A (en) 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
US6102904A (en) 1995-07-10 2000-08-15 Interventional Technologies, Inc. Device for injecting fluid into a wall of a blood vessel
US5693029A (en) 1995-07-10 1997-12-02 World Medical Manufacturing Corporation Pro-cell intra-cavity therapeutic agent delivery device
WO1997012629A1 (en) 1995-10-05 1997-04-10 Genentech, Inc. Improved angiogenesis using hepatocyte growth factor
US6190353B1 (en) 1995-10-13 2001-02-20 Transvascular, Inc. Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures
EP1704878B1 (en) 1995-12-18 2013-04-10 AngioDevice International GmbH Crosslinked polymer compositions and methods for their use
JP2000502682A (en) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド Local intravascular delivery of growth factors that promote angiogenesis
US5957941A (en) 1996-09-27 1999-09-28 Boston Scientific Corporation Catheter system and drive assembly thereof
US5827313A (en) 1996-09-27 1998-10-27 Boston Scientific Corporation Device for controlled longitudinal movement of an operative element within a catheter sheath and method
US5722403A (en) 1996-10-28 1998-03-03 Ep Technologies, Inc. Systems and methods using a porous electrode for ablating and visualizing interior tissue regions
US6120520A (en) 1997-05-27 2000-09-19 Angiotrax, Inc. Apparatus and methods for stimulating revascularization and/or tissue growth
US5968064A (en) 1997-02-28 1999-10-19 Lumend, Inc. Catheter system for treating a vascular occlusion
US6045565A (en) 1997-11-04 2000-04-04 Scimed Life Systems, Inc. Percutaneous myocardial revascularization growth factor mediums and method
EP0971641A4 (en) 1997-04-03 2003-08-13 Point Biomedical Corp Intravesical drug delivery system
US6179809B1 (en) 1997-09-24 2001-01-30 Eclipse Surgical Technologies, Inc. Drug delivery catheter with tip alignment
US6183432B1 (en) 1997-11-13 2001-02-06 Lumend, Inc. Guidewire and catheter with rotating and reciprocating symmetrical or asymmetrical distal tip
US6197324B1 (en) 1997-12-18 2001-03-06 C. R. Bard, Inc. System and methods for local delivery of an agent
US6217527B1 (en) 1998-09-30 2001-04-17 Lumend, Inc. Methods and apparatus for crossing vascular occlusions
US6231546B1 (en) 1998-01-13 2001-05-15 Lumend, Inc. Methods and apparatus for crossing total occlusions in blood vessels
DE69900746T2 (en) 1998-01-30 2002-08-14 Scios Inc CONTROLLED ADMINISTRATION OF PEPTIDES OR PROTEINS
US6201608B1 (en) 1998-03-13 2001-03-13 Optical Biopsy Technologies, Inc. Method and apparatus for measuring optical reflectivity and imaging through a scattering medium
US6175669B1 (en) 1998-03-30 2001-01-16 The Regents Of The Universtiy Of California Optical coherence domain reflectometry guidewire
CA2339330A1 (en) 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
US6191144B1 (en) 1998-08-17 2001-02-20 Warner-Lambert Company Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis
US6193763B1 (en) 1998-12-17 2001-02-27 Robert A. Mackin Apparatus and method for contemporaneous treatment and fluoroscopic mapping of body tissue
US6328229B1 (en) 1998-12-18 2001-12-11 Cohesion Technologies, Inc. Low volume mixing spray head for mixing and dispensing of two reactive fluid components
US6210392B1 (en) 1999-01-15 2001-04-03 Interventional Technologies, Inc. Method for treating a wall of a blood vessel
US6217554B1 (en) 1999-02-12 2001-04-17 Pharmaspec Corporation Methods and apparatus for delivering substances into extravascular tissue
US6296602B1 (en) 1999-03-17 2001-10-02 Transfusion Technologies Corporation Method for collecting platelets and other blood components from whole blood
US6312725B1 (en) 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
US6494862B1 (en) * 1999-07-13 2002-12-17 Advanced Cardiovascular Systems, Inc. Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway
WO2001024775A1 (en) 1999-10-01 2001-04-12 Essentia Biosystems, Inc. Gel-forming compositions
US6719970B1 (en) * 2000-07-10 2004-04-13 Alkermes Controlled Therapeutics, Inc. Method of generating cartilage
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US6554801B1 (en) 2000-10-26 2003-04-29 Advanced Cardiovascular Systems, Inc. Directional needle injection drug delivery device and method of use
US6692466B1 (en) * 2000-12-21 2004-02-17 Advanced Cardiovascular Systems, Inc. Drug delivery catheter with retractable needle
US20050015048A1 (en) * 2003-03-12 2005-01-20 Chiu Jessica G. Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof
US7250041B2 (en) * 2003-03-12 2007-07-31 Abbott Cardiovascular Systems Inc. Retrograde pressure regulated infusion
US7998112B2 (en) * 2003-09-30 2011-08-16 Abbott Cardiovascular Systems Inc. Deflectable catheter assembly and method of making same
NZ550964A (en) 2004-04-28 2011-05-27 Angiodevice Internat Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
MX2009001461A (en) * 2006-08-08 2009-07-02 Univ Texas Multistage delivery of active agents.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040070A2 (en) * 2000-11-15 2002-05-23 Bio Syntech Canada Inc. Method for restoring a damaged or degenerated intervertebral disc
WO2002087623A1 (en) * 2001-04-27 2002-11-07 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
WO2003064637A1 (en) * 2001-11-06 2003-08-07 Medtronic, Inc. Method and system for myocardial infarction repair
WO2004050013A2 (en) * 2002-11-29 2004-06-17 The Regents Of The University Of California Material compositions and related systems and methods for treating cardiac conditions
WO2004091592A2 (en) * 2003-04-15 2004-10-28 Guidant Corporation, V.I. Methods and compositions to treat myocardial conditions

Also Published As

Publication number Publication date
US7854944B2 (en) 2010-12-21
WO2006076121A2 (en) 2006-07-20
US20110070307A1 (en) 2011-03-24
US20060134070A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
WO2006076121A3 (en) Tissue regeneration
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
WO2006037049A3 (en) Application of a coating on a medical device
EP2366717A3 (en) Combination Cancer Immunotherapy with Co-Stimulatory Molecules
WO2009140421A3 (en) Polymeric carrier
WO2006107854A3 (en) Epidermal growth factor receptor gene copy number
WO2007145909A3 (en) Methods and compositions for treating post-myocardial infarction damage
HK1186406A1 (en) Method and carrier complexes for delivering molecules to cells
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
EP1775343A8 (en) Anticancer agent containing dendritic cell having rna virus transferred thereinto
JP2010179112A5 (en)
IL181337A0 (en) Transdermal therapeutic system comprising an adhesive layer, method for siliconizing the back layer of the system and use of said back layer
WO2008079997A3 (en) Implantable device, angiogenesis mechanism and methods
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
ZA200606951B (en) Catalyst carrier and catalyst composition processes for their preparation and their use
WO2007008200A8 (en) Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
EP2279726A3 (en) Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
NZ588587A (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
WO2007028512A3 (en) Magnetic-field controlled active substance transfer for aerosol therapy
EP1742654A4 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
MX2007000418A (en) Methods and reagents for treating honeybees for parasitic mites.
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
WO2007111927A3 (en) Odor neutralization apparatus and method
AU2003223494A8 (en) Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
EP1759582A4 (en) Preservative solution for cells, tissues and organs comprising rare sugar and presercation method with the use of the same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05857095

Country of ref document: EP

Kind code of ref document: A2